Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Search by expertise, name or affiliation
Turoctocog alfa and drug development for hemophilia A
Steven R. Lentz
, Stephanie Seremetis
, Janice Staber
, Roshni Kulkarni
Research output
:
Contribution to journal
›
Article
›
peer-review
3
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Turoctocog alfa and drug development for hemophilia A'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Drug Development
100%
Hemophilia
100%
Turoctocog Alfa
100%
Clinical Development
40%
Patient Demographics
20%
Expert Opinion
20%
Armamentarium
20%
Bleeding Episodes
20%
Guardian
20%
Area Cover
20%
Lessons Learned
20%
Replacement Therapy
20%
Treatment Access
20%
Multinational Trial
20%
Clinical Development Programs
20%
Production Methods
20%
Factor VIII Concentrate
20%
B Domain
20%
Severe Haemophilia A
20%
Recombinant Factor VIII
20%
Factor VIIIa
20%
Nonclinical Development
20%
Pharmacology, Toxicology and Pharmaceutical Science
Drug Development
100%
Recombinant Blood Clotting Factor 8
100%
Haemophilia A
100%
Blood Clotting Factor 8
33%
Replacement Therapy
16%
Blood Clotting Factor 8 Concentrate
16%